about
ACP Journal Club. Review: Dabigatran does not differ from vitamin K antagonists for mortality or major bleeding.Low-molecular-weight heparin biosimilars: potential implications for clinical practice. Australian Low-Molecular-Weight Heparin Biosimilar Working Group (ALBW).Drug Treatment of Venous Thromboembolism in the Elderly.Review: For warfarin reversal, prothrombin complex concentrates reduce mortality compared with fresh frozen plasma.Incidence of Venous Thromboembolism in Asian Populations: A Systematic Review.Simplified and original Wells rules plus age-adjusted D-dimer test were useful for ruling out suspected PE.Fresh frozen plasma and prothrombin concentrate transfusions in a South Australian teaching hospital: patterns of use and effects on international normalised ratios.Review: In patients with a first VTE, extended testing for undiagnosed cancer does not reduce mortality.Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trialClinical impact and course of major bleeding with edoxaban versus vitamin K antagonistsEarly vs deferred endovenous ablation reduced time to ulcer healing in venous leg ulcers with varicose veinsCharacteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY TrialAfter PCI and 3 mo of DAPT, P2Y12-inhibitor monotherapy was noninferior to DAPT at 12 moThrombosis: a major contributor to global disease burden
P50
Q38204688-B7439923-C175-4B3E-9011-65D2E91492C5Q38210858-88B50BE8-A8F4-4990-AC93-7372D53AAA79Q38851927-EA20F7D1-6163-446E-8AC9-D1D487CD81D2Q39043365-920B9836-55E6-4955-8725-0DDA25B760BCQ50048461-5765D966-8F04-4E05-97EF-253627732742Q50934736-A3218598-7B7C-497D-95A5-7539906D94CDQ51554594-EE379D66-ECA3-4FD2-936B-44DE0D51DA45Q52744705-75DEDCBC-6409-4AF1-836E-BDF5F6D2C950Q88245273-58306C97-2E25-436A-845C-1B3A31D25B5AQ89053370-0358EFB8-E3F0-4E35-B0EF-CA2266AA9356Q91054064-5E49711B-380C-4535-A89B-EB10C6390A31Q91076789-52B81731-E340-449D-AC1A-ADC36DDC68A3Q91324632-2992028C-0840-4F7C-8955-41B68BC68AF9Q95610412-2974A0DD-471A-4FA0-B90C-932423C7C77F
P50
description
researcher
@en
wetenschapper
@nl
name
Alexander S Gallus
@en
Alexander S Gallus
@nl
type
label
Alexander S Gallus
@en
Alexander S Gallus
@nl
prefLabel
Alexander S Gallus
@en
Alexander S Gallus
@nl
P31
P496
0000-0001-7347-9989